ATHENA Trial Tests Fat-Derived Stem Cells as a Treatment for Heart Failure


The FDA-approved ATHENA trial is the brainchild of stem cell researchers at the Texas Heart Institute at St. Luke’s Episcopal Hospital. The ATHENA trial is the first trial in the United States to examine the efficacy of adipose-derived regenerative cells or ADRCs as a treatment for a severe form of heart failure.

To harvest ADRCs, Texas Heart Institute researchers used a technique that was developed by Cytori Therapeutics, which is a biotechnology company that specializes in cell-based regenerative therapies. Previous clinical trials in Europe strongly suggest that such ADR-based therapies are quite safe and feasible. To date, physicians are the Texas Heart Institute have treated six patients as a part of the ATHENA trial.

athena_process_illustration_500x369.jpg

James Willerson, the president and medical director of the Texas Heart Institute, is the principal investigator in the ATHENA trial. Willerson said, “We have found that body fat tissue is a valuable source of regenerative stem cells that are relatively easy to access. We have high hopes for the therapeutic promise of this research and believe that it will lead quickly to larger trials.”

The subjects for the ATHENA trial are patients who suffer from chronic heart failure due to coronary heart disease. Coronary heart disease results from blockage of the coronary vessels and feed the heart muscle and limits the oxygen supply to the heart muscle, and consequently, the pumping activity of the heart muscle. Data from the American Heart Association reveals that there are about 5.1 million Americans who currently live with heart failure, and in many cases, the only viable treatment is a left ventricular assist device (LVAD) or a heart transplant. Unfortunately, there are only about 2,200 heart transplants a year due to a severe shortage of organs.

Coronary artery disease

Patients who are enrolled in the ATHENA trials are randomized and some will receive a placebo treatment and others will receive the experimental treatment. All patients will undergo liposuction in order to remove adipose or fat tissue. Processing of the fat tissue isolates the ADRCs, and the experimental patients will have these cells injected directly into their heart muscle, but the placebo patients will receive injections of culture medium or saline that contains no cells. ATHENA will measure several data endpoints that include objective measures of heart function, exercise capacity, and questionnaires that assess the symptoms and health-related quality-of-life.

The US trial will enroll a total of 45 patients at several centers around the country and these centers include the Texas Heart Institute, Minneapolis Heart Institute, Scripps Green Hospital in San Diego, CA, the University of Florida at Gainesville, and Cardiology P.C. in Birmingham. Patients are being enrolled.

Healthline has recently compiled the statistics on heart disease in an impressive and colorful manner at this link.

NCKU study: Nanomaterials help heart to heal


In advanced countries, heart disease is the major cause of death. In Taiwan, there are about 2 million patients with heart disease every year, and 400,000 deaths, mostly due to coronary artery disease, which leads to heart failure.

A research team led by Patrick C. H. Hsieh, an associate professor and cardiac surgeon at the National Cheng Kung University (NCKU) in Taiwan has discovered a new way to regenerate blood vessels by using nanofibers and a growth factor known as vascular endothelial growth factor (VEGF).

This new technology will help endogenous stem cells regenerate the heart and blood vessels and might be a promising approach to cure heart diseases. The president of NCKU, Hwung-Hweng Hwung, praised this research team’s achievements when he called Hsieh is “a good professor dedicated to scientific research that is beneficial to society.” According to Hsieh, NCKU will assist Hsieh’s team transfer this technology from the laboratory to the clinic in the hope that this novel treatment will be available for people with heart diseases.

Hsieh’s study combines tissue engineering, nanotechnology and controlled protein delivery in order to induce endogenous stem cells to regenerate blood vessels and improve cardiac function.

The growth factor, VEGF, is one of the main players for the growth and formation of blood vessels (see Ahluwalia A, Tarnawski AS. Critical role of hypoxia sensor–HIF-1α in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr Med Chem. 2012;19(1):90-7). Even though VEGF has been used in clinical settings as treatment for cardiovascular diseases, it has not worked terribly well (see Simón-Yarza T, et al., Theranostics. 2012;2(6):541-52). However, when VEGF was combined with nanomaterial, the results were quite different.

According to Hsieh: “The combination of nanomaterial with VEGF works well for the nanofibers to create a favorable microenvironment in the heart for recruiting stem cells.”

These experiments were done in rats and pigs, but the implantation of VEGF with led to the growth of newly formed blood vessels, which improved heart function without harmful side effects.

The laboratory animals were treated immediately after heart attacks were induced. Unfortunately, in human patients, this would not be possible. Instead this treatment might be effective if given in the first week after a heart attack, when stem-cell activity in the bone marrow and heart are still high.

This study was published by Science Translational Medicine on Wednesday, and the journals Science and Nature reported the NCUK study and noted it for its potential importance.